Resistance formation towards antiretroviral drugs in Eastern Africa

A single point mutation is sufficient to create substantial resistance towards nevirapine.

This resistance development will include resistance towards other drugs of the NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitors) class. The aim of this project is to develop and establish more sensitive and cheaper methods for the analysis of NNRTI-mutations

 

 

You are here:

Project Details

Project co-ordinator:
Andrea Kunz

Co-workers:
Andrea Hauser
Dr. Claudia Kücherer
Prof. Dr. Gundel Harms-Zwingenberger

Co-operation:
Robert Koch-Institut Berlin, Germany

Project duration:
2007-2008

Project status:
ongoing

Funding:
Charité

Papers

Publications:
Kunz A, Frank M, Mugenyi K, Kabasinguzi R, Weidenhammer A, Kurowski M, Kloft C, Harms G. 
Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. 
J Antimicrob Chemother 2009; 63:170-177.

Presentations:
Establishment and validation of pyrosequencing to identify nevirapine resistance mutations in the HIV-1 reverse transcriptase. Jahrestagung der Gesellschaft für Virologie, Heidelberg, 5-8. März 2008.

"Allele-specific, subtype A and subtype D specific real-time PCR for the detection of minor drug-resistant populations after nevirapine single-dose". XVII Internationalen AIDS Konferenz, Mexiko, 2008.

"Detection of minor drug-resistant populations in plasma of HIV-infected children and their mothers after single-dose nevirapine". XVII Internationalen AIDS Konferenz, Mexiko, 2008.

"Population Pharmacokinetics in Black Newborns for Nevirapine to Prevent HIV Transmission". 2nd World Conference on Magic Bullets (Ehrlich II), Nürnberg, 2008.
Poster "Nevirapine - Population pharmacokinetic model building and simulation for mothers and newborns". Page-Meeting, Marseille 2008.

"Population pharmacokinetics of nevirapine for HIV prevention in newborns". Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Bonn, 2008.